BioCardia, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BioCardia filed a revised De Novo pre-submission with FDA CDRH on October 1, 2026, for its Helix catheter for therapeutic and diagnostic agent delivery to the heart. FDA confirmed in August 2026 that it identified two potential pathways for marketing clearance and raised no safety or performance concerns based on 15 clinical trials with ~500 patients. FDA targets providing initial acceptance/refusal review within 15 days and written feedback within 70 days.
Why this rating
De Novo clearance of first-in-class device would be transformational for $9.7M company; expands partnership opportunities; material near-term regulatory milestone with defined timeline.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-9.6% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.01 | +10 min · unknown $1.03 ▲ 2.48% | +30 min · unknown $1.01 ▲ 0.00% | +1 hr · unknown $1.03 ▲ 1.98% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.